LP-183 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW)

• Victoria P Werth,
• Eric F Morand,
• Melinda Przetak,
• Flavie Moreau,
• Cristina Vazquez-Mateo,
• Andrew Bender,
• Sanjeev Roy,
• Aditee Deshpande,
• Ankita Deshmukh,
• Bharat Vaidyanathan,
• Mukhy Khursheed,
• David R Pearson

Affiliations

Victoria P Werth

2Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Eric F Morand

Rheumatology, Monash Medical Centre, Melbourne, Victoria, Australia

Melinda Przetak

3Research Unit – Neuroscience and Immunology, EMD Serono Research and Development institute, Inc., an affiliate of Merck KGaA, Billerica, MA, USA

Flavie Moreau

EMD Serono Research and Development Institute, Inc, Billerica, Massachusetts, USA; an affiliate of Merck KGaA, Darmstadt, Germany

Cristina Vazquez-Mateo

4EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, USA

Andrew Bender

2EMD Serono Research and Development Institute, Inc., Billerica, MA, USA

Sanjeev Roy

7Merck, Aubonne, Switzerland, a division of Merck KGaA, Darmstadt, Germany

Aditee Deshpande

3TIP Immunology, EMD Serono Research and Development institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA

Ankita Deshmukh

3TIP Immunology, EMD Serono Research and Development institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA

Bharat Vaidyanathan

3TIP Immunology, EMD Serono Research and Development institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA

Mukhy Khursheed

6Global Patient Safety, Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA

David R Pearson

8Department of Dermatology, University of Minnesota, Minneapolis, USA; *Presenter of abstract